Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Twist Bioscience Corp — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.47 (market cap $8.95B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Norwegian Cruise Line Holdings Ltd is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | TWST | |
|---|---|---|
Market Cap | $8.95B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $102.88 |
52-Week Low | $14.79 | $24.16 |
Enterprise Value | $23.92B | $5.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
